Published in Gene Therapy Weekly, September 7th, 2006
According to a study from the United States, "Our goal was to evaluate whether systemic administration of NV1042, an interleukin-12 (IL-12) - expressing oncolytic herpes simplex virus, and its noncytokine parental vector NV1023 are effective against pre-existing metastatic prostate cancer in an immunocompetent mice model.
"Metastatic TRAMP-C2 lung tumors established in C57Bl/6 or nude mice were treated on day 21 with four i.v. administrations...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.